Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: A Pediatric Oncology Group study

Anne-marie R Langevin, Steven D Weitman, John G. Kuhn, Susan E Weintraub, Sylvain Baruchel, Wayne Furman, Mark Bernstein, Susan Blaney, Teresa Vietti

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: To conduct a phase 1 trial of rebeccamycin analog (NSC #655649) in children with solid tumors to establish the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD); to establish the pharmacokinetic profile in children, and to document any evidence of antitumor activity. Methods: A 1-hour infusion of NSC #655649 was administered every 21 days to 17 patients younger than 21 years who had malignant tumors refractory to conventional therapy. Doses ranged from 450 mg/m2 to 760 mg/m2. Pharmacokinetics were done in at least three patients per dose level. The first course was used to determine DLT and MTD. Results: Sixteen patients on three dose levels were assessable for toxicities. At 760 mg/m2, four patients had dose-limiting neutropenia and thrombocytopenia. Pharmacokinetics were assessable in 13 patients. Plasma concentrations declined triexponentially and concentrations above the range of in vitro antitumor activity were maintained for 3 days. Analysis of urine extracts revealed the presence of an N-de-ethylated metabolite and probable involvement of cytochrome P450 isoenzyme(s) in the metabolism of NSC #655649. Pharmacodynamic studies showed a relationship between the area under the curve and percentage change in absolute neutrophil count in the Emax model (r2 = 0.56, P = 0.001). Conclusions: The recommended phase 2 dose of NSC #655649 administered as a 1-hour infusion every 21 days to children with solid tumors is 585 mg/m2. Both neutropenia and thrombocytopenia were found to be dose-limiting toxicities.

Original languageEnglish (US)
Pages (from-to)526-533
Number of pages8
JournalJournal of Pediatric Hematology/Oncology
Volume25
Issue number7
DOIs
StatePublished - Jul 2003

Fingerprint

Pediatrics
Maximum Tolerated Dose
Pharmacokinetics
Neoplasms
Neutropenia
Thrombocytopenia
Cytochrome P-450 Enzyme System
Isoenzymes
Area Under Curve
Neutrophils
rebeccamycin
Urine
Therapeutics

Keywords

  • Pediatric
  • Phase I trial
  • Rebeccamycin analog

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors : A Pediatric Oncology Group study. / Langevin, Anne-marie R; Weitman, Steven D; Kuhn, John G.; Weintraub, Susan E; Baruchel, Sylvain; Furman, Wayne; Bernstein, Mark; Blaney, Susan; Vietti, Teresa.

In: Journal of Pediatric Hematology/Oncology, Vol. 25, No. 7, 07.2003, p. 526-533.

Research output: Contribution to journalArticle

Langevin, Anne-marie R ; Weitman, Steven D ; Kuhn, John G. ; Weintraub, Susan E ; Baruchel, Sylvain ; Furman, Wayne ; Bernstein, Mark ; Blaney, Susan ; Vietti, Teresa. / Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors : A Pediatric Oncology Group study. In: Journal of Pediatric Hematology/Oncology. 2003 ; Vol. 25, No. 7. pp. 526-533.
@article{26b8854e915344bf9d9401ffef137d92,
title = "Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: A Pediatric Oncology Group study",
abstract = "Purpose: To conduct a phase 1 trial of rebeccamycin analog (NSC #655649) in children with solid tumors to establish the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD); to establish the pharmacokinetic profile in children, and to document any evidence of antitumor activity. Methods: A 1-hour infusion of NSC #655649 was administered every 21 days to 17 patients younger than 21 years who had malignant tumors refractory to conventional therapy. Doses ranged from 450 mg/m2 to 760 mg/m2. Pharmacokinetics were done in at least three patients per dose level. The first course was used to determine DLT and MTD. Results: Sixteen patients on three dose levels were assessable for toxicities. At 760 mg/m2, four patients had dose-limiting neutropenia and thrombocytopenia. Pharmacokinetics were assessable in 13 patients. Plasma concentrations declined triexponentially and concentrations above the range of in vitro antitumor activity were maintained for 3 days. Analysis of urine extracts revealed the presence of an N-de-ethylated metabolite and probable involvement of cytochrome P450 isoenzyme(s) in the metabolism of NSC #655649. Pharmacodynamic studies showed a relationship between the area under the curve and percentage change in absolute neutrophil count in the Emax model (r2 = 0.56, P = 0.001). Conclusions: The recommended phase 2 dose of NSC #655649 administered as a 1-hour infusion every 21 days to children with solid tumors is 585 mg/m2. Both neutropenia and thrombocytopenia were found to be dose-limiting toxicities.",
keywords = "Pediatric, Phase I trial, Rebeccamycin analog",
author = "Langevin, {Anne-marie R} and Weitman, {Steven D} and Kuhn, {John G.} and Weintraub, {Susan E} and Sylvain Baruchel and Wayne Furman and Mark Bernstein and Susan Blaney and Teresa Vietti",
year = "2003",
month = "7",
doi = "10.1097/00043426-200307000-00006",
language = "English (US)",
volume = "25",
pages = "526--533",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors

T2 - A Pediatric Oncology Group study

AU - Langevin, Anne-marie R

AU - Weitman, Steven D

AU - Kuhn, John G.

AU - Weintraub, Susan E

AU - Baruchel, Sylvain

AU - Furman, Wayne

AU - Bernstein, Mark

AU - Blaney, Susan

AU - Vietti, Teresa

PY - 2003/7

Y1 - 2003/7

N2 - Purpose: To conduct a phase 1 trial of rebeccamycin analog (NSC #655649) in children with solid tumors to establish the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD); to establish the pharmacokinetic profile in children, and to document any evidence of antitumor activity. Methods: A 1-hour infusion of NSC #655649 was administered every 21 days to 17 patients younger than 21 years who had malignant tumors refractory to conventional therapy. Doses ranged from 450 mg/m2 to 760 mg/m2. Pharmacokinetics were done in at least three patients per dose level. The first course was used to determine DLT and MTD. Results: Sixteen patients on three dose levels were assessable for toxicities. At 760 mg/m2, four patients had dose-limiting neutropenia and thrombocytopenia. Pharmacokinetics were assessable in 13 patients. Plasma concentrations declined triexponentially and concentrations above the range of in vitro antitumor activity were maintained for 3 days. Analysis of urine extracts revealed the presence of an N-de-ethylated metabolite and probable involvement of cytochrome P450 isoenzyme(s) in the metabolism of NSC #655649. Pharmacodynamic studies showed a relationship between the area under the curve and percentage change in absolute neutrophil count in the Emax model (r2 = 0.56, P = 0.001). Conclusions: The recommended phase 2 dose of NSC #655649 administered as a 1-hour infusion every 21 days to children with solid tumors is 585 mg/m2. Both neutropenia and thrombocytopenia were found to be dose-limiting toxicities.

AB - Purpose: To conduct a phase 1 trial of rebeccamycin analog (NSC #655649) in children with solid tumors to establish the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD); to establish the pharmacokinetic profile in children, and to document any evidence of antitumor activity. Methods: A 1-hour infusion of NSC #655649 was administered every 21 days to 17 patients younger than 21 years who had malignant tumors refractory to conventional therapy. Doses ranged from 450 mg/m2 to 760 mg/m2. Pharmacokinetics were done in at least three patients per dose level. The first course was used to determine DLT and MTD. Results: Sixteen patients on three dose levels were assessable for toxicities. At 760 mg/m2, four patients had dose-limiting neutropenia and thrombocytopenia. Pharmacokinetics were assessable in 13 patients. Plasma concentrations declined triexponentially and concentrations above the range of in vitro antitumor activity were maintained for 3 days. Analysis of urine extracts revealed the presence of an N-de-ethylated metabolite and probable involvement of cytochrome P450 isoenzyme(s) in the metabolism of NSC #655649. Pharmacodynamic studies showed a relationship between the area under the curve and percentage change in absolute neutrophil count in the Emax model (r2 = 0.56, P = 0.001). Conclusions: The recommended phase 2 dose of NSC #655649 administered as a 1-hour infusion every 21 days to children with solid tumors is 585 mg/m2. Both neutropenia and thrombocytopenia were found to be dose-limiting toxicities.

KW - Pediatric

KW - Phase I trial

KW - Rebeccamycin analog

UR - http://www.scopus.com/inward/record.url?scp=0038310028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038310028&partnerID=8YFLogxK

U2 - 10.1097/00043426-200307000-00006

DO - 10.1097/00043426-200307000-00006

M3 - Article

C2 - 12847318

AN - SCOPUS:0038310028

VL - 25

SP - 526

EP - 533

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 7

ER -